To end tuberculosis in our lifetime!
The goal is ambitious but achievable with sufficient effort. Tuberculosis (TB) is the leading cause of death worldwide from a single infectious disease, claiming around 1.2 million lives each year. Of the more than 10 million people who fall ill annually, one in four will not be diagnosed, and one in three will not receive treatment. This underscores the need for a comprehensive approach to strengthen all aspects of TB care, from prevention and diagnostics to treatment and follow-up.
Main focus
By combining clinical epidemiology with microbiology and pharmacology, we generate evidence that directly informs public health screening strategies, clinical care and guideline development. For example, our work on drug dosing and exposure in patients with MDR-TB contributes to safer and more effective treatment regimens. In a Swedish context, we are evaluating Model-Informed Precision Dosing (MIPD) to improve TB treatment.
We also conduct diagnostic accuracy studies in international settings, such as Vietnam and Lesotho, to assess new point-of-care tests that may improve detection of latent and active TB, thus enhancing early intervention and prevention.
Societal benefits of our research
Our research contributes solutions to the goal of ending TB in our lifetime. Through collaborations with:
- Friends for International TB Relief, Vietnam
- Partners in Health, Lesotho
- Harvard Medical School, USA
- University of Sydney, Australia
We aim to find scalable interventions that benefit patients and health systems alike.